Results 41 to 50 of about 79,537 (233)

In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. [PDF]

, 2016
Aberrant Hedgehog (Hh)/glioma-associated oncogene (GLI) signaling has been implicated in cancer progression. Here, we analyzed GLI1, Sonic Hedgehog (Shh) and NF-κB expression in 51 breast cancer (ductal carcinoma) tissues using immunohistochemistry ...
Bei, R., Benvenuto, M, Bonanno, E, Cucchi, Danilo, DE SMAELE, Enrico, DI STEFANO, Enrica, Fantini, M, Frajese, Gv, Gulino, Alberto, Masuelli, Laura, Mattera, Rosanna, Modesti, A, Orlandi, A, Screpanti, Isabella   +13 more
core   +1 more source

hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. [PDF]

, 2015
Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 ...
Circo, R, De Maria, R, Di Benedetto, A, Di Modugno, F, Matteoni, S, Melchionna, R, Mottolese, M, Nisticò, P. 1., Palermo, Belinda, Soddu, S, Spada, Sheila, Trono, P   +11 more
core   +2 more sources

A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing

Advanced Healthcare Materials, EarlyView.
This study presents the first entirely isogenic heart‐on‐chip, unifying cardiomyocytes, fibroblasts, and endothelial cells from a single iPSC source. The platform reveals a critical biological insight: the endothelium actively shields cardiac tissue from drug‐induced toxicity, challenging the predictive accuracy of conventional, avascular models for ...
Karine Tadevosyan, Jose Yeste, Mar Alvarez, Denise Marrero, Laura Casado‐Medina, Yvonne Richaud‐Patin, Olalla García‐Iglesias, Jagoda Litowczenko, Alba Morillas Garcia, Anton Guimerà, Xavi Illa, Rosa Villa, Angel Raya   +12 more
wiley   +1 more source

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report

Journal of International Medical Research, 2020
The ErbB family is composed of four cell membrane receptors: ErbB-1 (epidermal growth factor receptor or human epidermal growth factor receptor [HER]1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4).
Mengyao Sun, Ye Guo, Xu Wang, Chao Sun, Jiangbo Shao, Yinghui Xu, Shi Qiu, Kewei Ma   +7 more
doaj   +1 more source

The basic biology of erbB-2 and its participation in colorectal cancers [PDF]

, 2005
ErbB-2 is one of Tour cell surface growth factor receptors involved in transmission of signals controlling normal cell growth and differentiation. A range of growth factors serve as ligands, but none is specific for the ErbB-2 receptor.
Bryś, Magdalena, Krajewska, Wanda M., Stawińska, Magdalena   +2 more
core  

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS, Andreasen PA, Arie van Dalen, ASCO Expert Panel, Barak V, Barnes DM, Baselga J, Bast RC, Benraad TH, Bieglmayer C, Blamey RW, Bonadonna G, Chan DW, Chebil G, Chu KC, Colditz G, Conneely OM, De Koning H, Devine PL, Dixon AR, Dnistrian AM, Dnistrian AM, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Early Breast Cancer Trialist's, Early Breast Cancer Trialists Collaborative Group, Early Breast Cancer Trialists Collaborative Group, Easton DF, Ebeling FC, Ebeling FG, Eifel P, Einarsson R, Ekbom A, Elledge RM, Fisher B, Fitzgibbons PL, Gion M, Gion M, Guadagni F, Gyö, Harries M, Harvey JM, Helena Goike, Holli K, Holli K, Iwase H, Jager W, Jensen EV, Kamel EM, Konecny G, Kurebayashi J, Lamerz R, Leake R, Leers M, Leers MP, Leers MP, Legha SS, Leyland-Jones B, Look MP, Loomer L, Loprinzi CL, Madigan MP, Marius Nap, Massimo Gion, McCarty, McLaughlin R, Merimsky O, Michael J. Duffy, Mohsin SK, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Morrow M, Nakata B, Newcomb P, Nicolini A, Nicolini A, Nicolini A, O'Hanlon DM, Paik S, Palazzo S, Parker SL, Parkin DN, Pecking AP, Pertschuk LP, Pertschuk LP, Petra Stieber, Piccart MJ, Price MR, Rafael Molina, Robertson JFR, Robertson JFR, Rogers CE, Roland Einarsson, Rolf Lamerz, Romer M, Rosselli del Turco M, Safi F, Schapira DV, Schapira DV, Sjostrom J, Slamon D, Soletormos G, Soletormos G, Soletormos G, Soletormos G, Stieber P, Sturgeon CM, Sweep CGJ, Tabar L, The GIVIO, The GIVIO, Theriault RL, Thorpe SM, Tomlinson IP, Tondini C, Van Dalen A, Van Dalen A, van Dalen A, van Dalen A, Van Dalen A, van Dalen A, Veronesi U, Vivian Barak, Vizcarra E, Vyzula R, Weihua Z, Williams MR, Yamauchi H, Zucchelli GC   +136 more
core   +1 more source

Enhanced Infection Resistance and Regenerative Healing of Titanium Implants via Peptide‐Loaded Biodegradable Coatings

Advanced Materials Technologies, EarlyView.
This study presents a new biodegradable coating for titanium implants using a natural antimicrobial peptide, caerin 1.9. Applied via solvent casting, the coating offers sustained antibacterial protection and promotes healing. Tested on 3D‐printed porous titanium scaffolds, it effectively prevented infection—including against resistant bacteria—while ...
Hejie Li, Tianfang Wang, Nicolas Soro, Guoying Ni, Meg Allom, D. İpek Kurtböke, Xiaosong Liu, Damon Kent   +7 more
wiley   +1 more source

Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach.

Folia Histochemica et Cytobiologica, 2010
The c-erbB-2 (HER-2/neu), EGF and EGFR (erbB-1) proteins, members of the epidermal growth factor receptor family, play a role in cell growth by binding to cell membrane receptors.
Katarzyna Guzinska-Ustymowicz, Jolanta Czyzewska, Andrzej Kemona   +2 more
doaj   +1 more source

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

, 2005
Introduction: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Gunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, Elke Jäger, Salah-Eddin Al-Batran, Sibylle Loibl, Akin Atmaca, Christian Cimpoiasu, Antje Neumann, Aklil Abera, Alexander Knuth, Manfred Kaufmann, Dirk Jäger, Alexander B Maurer, Winfried S Wels, MA Olayioye, Y Yarden, J Mendelsohn, DJ Slamon, CL Vogel, I Pastan, W Wels, RJ Kreitman, W Wels, W Wels, IM Harwerth, BH Iglewski, A Keppler-Hafkemeyer, M Schmidt, A Spyridonidis, M Azemar, L Wang, U Altenschmidt, M Maurer-Gebhard, JK Batra, Y Reiter, LH Pai-Scherf, M Azemar, WMA, M Maurer-Gebhard, FDA, J Schumann, M Onda, NJ Olsen, YL Yip, B Gerstmayer, DL Keefe, HS Cho, RJ Kreitman, RJ Kreitman   +49 more
core   +1 more source

Single‐Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re‐Sensitizer Drugs in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
To combat BET inhibitor resistance in triple‐negative breast cancer, we developed two single‐cell computational frameworks. FR20 quantifies resistance by integrating ferroptosis‐related gene signatures, while D‐FR20 screens for potential re‐sensitizers.
Haizhou Liu, Mengqin Yuan, Yini Shang, Jiahao Chen, Fei Hou, Lihong Wang, Wei Jiang   +6 more
wiley   +1 more source